Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Profitability
This table compares Tarsus Pharmaceuticals and Sunshine Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tarsus Pharmaceuticals | -9.02% | -14.19% | -8.89% |
| Sunshine Biopharma | -17.86% | -27.14% | -21.14% |
Institutional & Insider Ownership
90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tarsus Pharmaceuticals | $451.36 million | 5.83 | -$66.42 million | ($1.14) | -53.69 |
| Sunshine Biopharma | $36.31 million | 0.14 | -$5.97 million | ($1.48) | -0.71 |
Sunshine Biopharma has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Tarsus Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for Tarsus Pharmaceuticals and Sunshine Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tarsus Pharmaceuticals | 1 | 2 | 4 | 2 | 2.78 |
| Sunshine Biopharma | 1 | 0 | 1 | 0 | 2.00 |
Tarsus Pharmaceuticals presently has a consensus target price of $90.67, suggesting a potential upside of 48.12%. Sunshine Biopharma has a consensus target price of $7.00, suggesting a potential upside of 566.67%. Given Sunshine Biopharma’s higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Tarsus Pharmaceuticals.
Summary
Tarsus Pharmaceuticals beats Sunshine Biopharma on 11 of the 15 factors compared between the two stocks.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
